Ichikawa, W
Uehara, K
Minamimura, K
Tanaka, C
Takii, Y
Miyauchi, H
Sadahiro, S
Fujita, K
Moriwaki, T
Nakamura, M
Takahashi, T
Tsuji, A
Shinozaki, K
Morita, S
Ando, Y
Okutani, Y
Sugihara, M
Sugiyama, T
Ohashi, Y
Sakata, Y
Article History
Received: 5 December 2014
Revised: 16 February 2015
Accepted: 7 March 2015
First Online: 16 April 2015
Competing interests
: WI is a consultant/advisory board member of Daiichi Sankyo and Merck-Serono. KU, KM, YT, HM, SS, MN, AT, and KS report receiving commercial research funds from Daiichi Sankyo. TM reports receiving commercial research funds from Daiichi Sankyo, Taiho Pharmaceutical, and Sanofi. SM is a consultant/advisory board member of Daiichi Sankyo and Taiho Pharmaceutical, and reports receiving commercial research funds from Daiichi Sankyo. YA is a consultant/advisory board member of Daiichi Sankyo, Kowa, GlaxoSmithKline, Novartis, PAREXEL International, and Boehringer Ingelheim, and reports receiving commercial research fund from Novartis. YOku and MS are full-time employees of Daiichi Sankyo. TS and YS are consultant/advisory board members of Daiichi Sankyo. YOha has a leadership role and owns stock of Statcom, is a consultant/advisory board member of Daiichi Sankyo, reports receiving commercial research funds from Astellas Pharma and Takeda Pharmaceutical, and has received travel accommodations from Yakult. No potential conflicts of interest were disclosed by the other authors.